MGNX - MacroGenics Inc Stock Price, Fair Value and News

$1.41-0.01 (-0.70%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MGNX Price Action

Last 7 days

-4.7%

Last 30 days

-10.8%

Last 90 days

-27.3%

Trailing 12 Months

-59.0%

MGNX RSI Chart

MGNX Valuation

Market Cap

89.2M

Price/Earnings (Trailing)

-1.18

Price/Sales (Trailing)

0.7

EV/EBITDA

0.26

Price/Free Cashflow

-0.54

MGNX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MGNX Fundamentals

MGNX Revenue

Revenue (TTM)

127.6M

Rev. Growth (Yr)

-34.21%

Rev. Growth (Qtr)

227.5%

MGNX Earnings

Earnings (TTM)

-75.9M

Earnings Growth (Yr)

-70.13%

Earnings Growth (Qtr)

146.4%

MGNX Profitability

EBT Margin

17.64%

Return on Equity

-113.26%

Return on Assets

-28.03%

Free Cashflow Yield

-184.72%

MGNX Investor Care

Shares Dilution (1Y)

0.79%

Diluted EPS (TTM)

-1.19

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	154.1M	165.5M	127.6M	0
2024	43.4M	41.0M	141.3M	150.0M
2023	165.3M	152.5M	121.1M	58.7M
2022	71.7M	66.9M	93.0M	151.9M
2021	108.1M	118.6M	116.0M	77.4M
2020	68.2M	77.9M	77.4M	104.9M
2019	65.1M	56.8M	54.8M	64.2M
2018	133.3M	108.9M	84.5M	60.1M
2017	108.3M	124.8M	141.3M	157.7M
2016	98.6M	96.4M	94.1M	91.9M
2015	104.4M	101.9M	98.2M	100.9M
2014	62.2M	59.1M	57.2M	47.8M
2013	53.9M	48.8M	52.9M	58.0M
2012	58.9M	60.5M	62.2M	63.8M
2011	0	0	0	57.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 ÃƒÆ’Ã¢â‚¬â€ CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B ÃƒÆ’Ã¢â‚¬â€ CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

CEO	Dr. Scott Koenig M.D., Ph.D.
WEBSITE	macrogenics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	357

MacroGenics Inc Frequently Asked Questions

What is the ticker symbol for MacroGenics Inc? What does MGNX stand for in stocks?

MGNX is the stock ticker symbol of MacroGenics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MacroGenics Inc (MGNX)?

As of Wed Dec 03 2025, market cap of MacroGenics Inc is 89.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MGNX stock?

You can check MGNX's fair value in chart for subscribers.

Is MacroGenics Inc a good stock to buy?

The fair value guage provides a quick view whether MGNX is over valued or under valued. Whether MacroGenics Inc is cheap or expensive depends on the assumptions which impact MacroGenics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MGNX.

What is MacroGenics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, MGNX's PE ratio (Price to Earnings) is -1.18 and Price to Sales (PS) ratio is 0.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MGNX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MacroGenics Inc's stock?

In the past 10 years, MacroGenics Inc has provided -0.274 (multiply by 100 for percentage) rate of return.